REPOST (Now with less picking on Craig!) I asked

New Post Public Reply Private Reply Replies (0) Message Board
Respert24
575
REPOST

(Now with less picking on Craig!)

I asked ChatGPT if AI will be able to replace human trials for investigational drug approvals in the future. Here is what she* said.

*Remember when Dishwalla sung about god being a woman in a way that you just knew meant they were trying to be far deeper than they were? Yeah, uh, me neither.

ChatGPT Says:


As of my last knowledge update in September 2021, AI has made significant strides in drug discovery and development, but completely replacing human trials for investigational drug approvals is a complex and multifaceted challenge. Here are some factors to consider:

1. Complexity of Human Biology: Human bodies are incredibly complex, and the interactions between drugs and our physiology are intricate and varied. While AI can simulate some of these interactions in silico (in a computer), it is challenging to capture the full complexity of human biology in a virtual environment.

2. Safety and Efficacy: One of the primary goals of clinical trials is to determine the safety and efficacy of a drug in humans. This involves not only looking at how a drug interacts with the body, but also understanding its impact on different patient populations, potential side effects, and long-term effects. AI can assist in the early stages of drug development, but understanding these aspects requires real-world trials.

3. Unforeseen Interactions: New drugs can have unforeseen interactions with existing medications, or with specific genetic or environmental factors. These interactions are difficult to predict using AI alone.

4. Regulatory Approval and Ethical Considerations: Regulatory bodies, such as the FDA in the United States, have established rigorous standards for drug approval. These standards are based on a wealth of historical evidence and prioritize patient safety. Moving from human trials to a solely AI-based system would require a major shift in global regulatory frameworks.

5. Patient Variability: Humans are highly variable. Factors like age, genetics, lifestyle, and environment can significantly impact how individuals respond to drugs. Clinical trials are designed to capture this variability.

6. Real-World Data Challenges: While AI can analyze large amounts of data, much of it comes from controlled clinical trial environments. Real-world data is messier and often harder to interpret. Incorporating this kind of data into a solely AI-driven approval process would be a significant challenge.

7. Ethical Considerations and Public Trust: There are ethical considerations surrounding the use of AI in healthcare. Patients and the public need to trust that new drugs have been thoroughly tested and are safe.

While AI is revolutionizing drug discovery by expediting the initial stages of identifying potential drug candidates, predicting their behavior, and even suggesting combinations, it is unlikely, at least in the foreseeable future, to fully replace human trials for investigational drug approvals. The gold standard of clinical trials serves a vital role in ensuring patient safety and drug efficacy. The future likely involves a synergistic relationship between AI and traditional clinical trials, with AI aiding in the design and optimization of trials.



Now that I've put that subject to bed, I also asked ChatGPT whether or not it thinks Cytodyn will have any catalysts hit this month.

It claimed it hasn't been updated in a couple years and can't predict the future, which is bullshit. I can't believe I'm not allowed to just hammer the keys on my laptop into questions that get immediately and accurately answered. What the fuck am I getting for the $1,000 I spent on this Lenovo laptop then?

Sticky keys?

That's it?

Bummer.

Oh wait, I do remember that there's one other thing I get with this laptop. Every month it will decide that it no longer has fingerprint recognition. Then after some updates it'll be like, Hey buddy, wanna use your fingerprint? I'm all ready for it. Which finger are you gonna use? Pointer? Nice call. Strong choice, the pointer. Now nestle that thing up on this tiny square and let's open your laptop. Mmm, I'm sure McAfee missed you while you were gone. Wanna scan some files together? Watch some black boxes needlessly flash on the screen for a nanosecond and never come back to explain why the hell you needed to see it? Maybe pop up an insufferable amount of reminders about what McAfee could do for you if you'd just let it? Why aren't you letting McAfee help you? McAfee can teach you many things, but McAfee won't beg. Come to Omaha with McAfee and let McAfee introduce you to some new experiences. Hey, where are you going? Reddit? Oh come on, it's a cesspool over there and they no longer let you give those little widget emoji things, I heard. Hey! Remember when you could buzz people on yahoo messenger? That was fun. A simple pleasure. Like making the dial up internet sounds back when you couldn't just connect in a millisecond, you had to wait for your computer to scream at you in various pitches for like ten seconds first. And you needed a CD at one point! Awww, CD's were the shit. I miss em. Even a Dishwalla album seemed cool when it was packaged in that unnecessarily sized rectangle package that only had the disc in the top half with the bottom half existing for no apparent reason.

I guess what I'm trying to say is buy low and sell high. Or, buy low then high, then chase it down and keep buying, and then say you're not going to buy any more but then buy more multiple times because it's so goddamn cheap right now. Then sit back and wait for the dominoes to start falling. But also buy more between now and then.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyde Park Hospitality LLC Allegedly Fails to Reimburse Expenses

Updated Category News Views 575

Allegations Against Hyde Park Hospitality LLC Hyde Park Hospitality LLC, a key player in the hospitality industry, is facing serious allegations regarding their reimbursement policies. It has been claimed that the company has not compensated its employees for business-related expenses, including the use of personal cell phones for company duties. This situation raises...

Continue Reading
Miami International Holdings Celebrates Gender Equality in Finance

Updated Category News Views 104

Miami International Holdings Celebrates Gender Equality in Finance Miami International Holdings, Inc. (MIH) proudly participated in a significant event to honor gender equality in the finance sector. The company ceremoniously rang the opening bell at its Princeton, N.J. headquarters, marking its commitment to supporting women in the finance industry. This event aligns...

Continue Reading
Crossject's Capital Raise and New Ventures for ZEPIZURE

Updated Category News Views 202

Crossject Secures Funding for Future Development Crossject, a pioneering specialty pharmaceutical company, has successfully completed a capital increase totaling EUR 7.2 million. This funding comes from the issuance of 3,635,756 shares at a subscription price of EUR 1.6012, equating to about 8.8% of the company's existing share capital. Moreover, the transaction includes...

Continue Reading
Understanding Burford Capital's Upcoming Dividend in GBP

Updated Category News Views 73

Burford Capital's Interim Dividend Announcement Burford Capital Limited, a well-known finance and asset management firm that specializes in law, has announced significant updates regarding its interim dividend. This dividend is an important aspect for investors holding ordinary shares as it directly impacts their returns. Pound Sterling Conversion Rate Details The interim...

Continue Reading
Cole Haan Launches GrandPrø Tennis 2.0 for 21st Century Style

Updated Category News Views 101

Cole Haan Introduces the GrandPrø Tennis 2.0 Cole Haan is excited to reveal the GrandPrø Tennis 2.0, showcasing a new era of style and comfort aimed at modern consumers. This innovative sneaker retains the lightness that the brand is known for while integrating advanced technology for enhanced performance. Revolutionary Features of the GrandPrø Tennis 2.0 The GrandPrø...

Continue Reading